- Home
- LEGN vs HALO Comparison
LEGN vs HALO Comparison
Compare LEGN & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGN
- HALO
- Stock Information
- Founded
- LEGN 2014
- HALO 1998
- Country
- LEGN United States
- HALO United States
- Employees
- LEGN N/A
- HALO N/A
- Industry
- LEGN Biotechnology: Pharmaceutical Preparations
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LEGN Health Care
- HALO Health Care
- Exchange
- LEGN Nasdaq
- HALO Nasdaq
- Market Cap
- LEGN 7.0B
- HALO 7.4B
- IPO Year
- LEGN 2020
- HALO N/A
- Fundamental
- Price
- LEGN $28.33
- HALO $53.93
- Analyst Decision
- LEGN Strong Buy
- HALO Buy
- Analyst Count
- LEGN 13
- HALO 9
- Target Price
- LEGN $75.67
- HALO $63.56
- AVG Volume (30 Days)
- LEGN 1.6M
- HALO 3.3M
- Earning Date
- LEGN 05-13-2025
- HALO 05-06-2025
- Dividend Yield
- LEGN N/A
- HALO N/A
- EPS Growth
- LEGN N/A
- HALO 55.40
- EPS
- LEGN N/A
- HALO 3.76
- Revenue
- LEGN $728,303,000.00
- HALO $1,084,306,000.00
- Revenue This Year
- LEGN $64.21
- HALO $25.77
- Revenue Next Year
- LEGN $53.69
- HALO $18.01
- P/E Ratio
- LEGN N/A
- HALO $14.34
- Revenue Growth
- LEGN 112.46
- HALO 25.64
- 52 Week Low
- LEGN $27.34
- HALO $42.01
- 52 Week High
- LEGN $60.87
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- LEGN 36.81
- HALO 43.12
- Support Level
- LEGN $27.34
- HALO $47.50
- Resistance Level
- LEGN $33.30
- HALO $69.94
- Average True Range (ATR)
- LEGN 1.91
- HALO 3.40
- MACD
- LEGN -0.30
- HALO -0.89
- Stochastic Oscillator
- LEGN 13.51
- HALO 27.94
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.